A dominant negative inhibitor of the p85 subunit of Pi3K similarly blocked anchorage independent growth, providing further evidence that selective inhibition of this pathway may be particularly useful when treating HER-2 overexpressing breast cancers [45]. This evidence concerns the gene ERBB2 and breast carcinoma.